Furosemide oral tablet [Regulatives / Guidelines]

posted by Ibrahim Komeil – Egypt, 2019-11-18 10:03 (1678 d 04:30 ago) – Posting: # 20818
Views: 1,407

Dear all

I would like to ask about bioequivalence study for Furosemide oral tablet. It is listed in FDA draft guidance that it is not high variable drug and i can use 2 way crossover design. However, i read EMA guidelines and MHRA guidelines assure its high interasubject variability so they recommend to have partial replicated design applying normal acceptance range (80%-125%), so what do you think about these data upon on your experience ?

Complete thread:

UA Flag
Activity
 Admin contact
23,059 posts in 4,841 threads, 1,649 registered users;
37 visitors (0 registered, 37 guests [including 6 identified bots]).
Forum time: 15:34 CEST (Europe/Vienna)

There are only two kinds of scholars;
those who love ideas and those who hate them.    Emile Chartier

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5